Nasdaq Dsgn News Today

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now directly owns […]

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid acquired 9,156 shares of Design Therapeutics stock in a transaction on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the purchase, the director now owns 9,156 […]

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid bought 9,156 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now owns 9,156 […]

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has earned an average rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold rating. The average 1 year price target among brokerages that have issued a report on the stock in the […]

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has received an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued ratings on the stock in […]

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating. The average 12 month price target among brokerages that have issued a report on […]

Design Therapeutics (NASDAQ:DSGN – Free Report) had its price target decreased by Royal Bank of Canada from $7.00 to $4.00 in a report published on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock. A number of other research firms have also issued reports on DSGN. SVB […]

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 3,120,000 shares, an increase of 6.1% from the October 15th total of 2,940,000 shares. Based on an average trading volume of 938,000 shares, the short-interest ratio […]

Design Therapeutics (NASDAQ:DSGN – Get Free Report) was downgraded by investment analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a note issued to investors on Tuesday, Briefing.com reports. They currently have a $6.00 target price on the stock, down from their previous target price of $42.00. Piper Sandler’s price target […]

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) have earned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating. The average twelve-month price objective among analysts that have covered the stock in the […]